Elanco Animal Health INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Elanco Animal Health Incorporated announced its 2026 Annual Meeting of Shareholders, detailing director nominations, executive compensation, and auditor ratification.
NYSE
Elanco Animal Health Incorporated announces its 2025 Annual Meeting of Shareholders to be held virtually on May 16, 2025.
NYSE
Elanco Animal Health reports strong 2024 performance and outlines strategic priorities for continued growth in 2025, while also announcing board changes.
NYSE
Elanco Animal Health Incorporated has filed a definitive proxy statement with the SEC.
NYSE
Elanco is asking shareholders to approve key governance changes, including declassifying the board and adopting a majority vote standard for director elections, while also preparing for a leadership transition with a new Board Chairman.
NYSE
Elanco responds to Ancora Holdings Group's press release, emphasizing its commitment to its strategy, recent stock performance, and continued shareholder engagement.
NYSE
Elanco defends its strategy and board composition against Ancora Holdings' nomination of director candidates, highlighting recent stock performance and operational improvements.